Isabel Weigand

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Author Correction: 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.

Author Correction: 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.

Journal: Nature

Published: March 25, 2026

Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFNγ-dependent CXCL9 secretion.

Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFNγ-dependent CXCL9 secretion.

Journal: Scientific reports

Published: November 12, 2025

Adrenocortical Mitochondria-Associated Membranes: Isolation, Characterization, and Lipidoproteomic Response to Mitotane.

Adrenocortical Mitochondria-Associated Membranes: Isolation, Characterization, and Lipidoproteomic Response to Mitotane.

Journal: Journal of the Endocrine Society

Published: July 22, 2025

Mitotane treatment of adrenocortical carcinoma induces tumoural secretion of GDF-15: impact on poor prognosis and impaired responsiveness to immunotherapy.

Mitotane treatment of adrenocortical carcinoma induces tumoural secretion of GDF-15: impact on poor prognosis and impaired responsiveness to immunotherapy.

Journal: European journal of endocrinology

Published: November 25, 2024

Wnt/β-catenin pathway activation is associated with glucocorticoid secretion in adrenocortical carcinoma, but not directly with immune cell infiltration.

Wnt/β-catenin pathway activation is associated with glucocorticoid secretion in adrenocortical carcinoma, but not directly with immune cell infiltration.

Journal: Frontiers in endocrinology

Published: September 26, 2024

A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples.

A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples.

Journal: Cancer research communications

Published: February 14, 2024

High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma - A Single Center Case Series.

High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma - A Single Center Case Series.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

Published: September 25, 2023

FSCN1 as a new druggable target in adrenocortical carcinoma.

FSCN1 as a new druggable target in adrenocortical carcinoma.

Journal: International journal of cancer

Published: November 21, 2022

Metabolic heterogeneity in adrenocortical carcinoma impacts patient outcomes.

Metabolic heterogeneity in adrenocortical carcinoma impacts patient outcomes.

Journal: JCI insight

Published: November 08, 2022

7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.

7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.

Journal: Nature

Published: September 27, 2021

Steroid Sulfation in Adrenal Tumors.

Steroid Sulfation in Adrenal Tumors.

Journal: The Journal of clinical endocrinology and metabolism

Published: January 11, 2021

A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden.

A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden.

Journal: European journal of endocrinology

Published: December 10, 2020

Showing 1-12 of 36

Last Updated: 09/26/2026